Tango Therapeutics (NASDAQ:TNGX) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Key Points

• Modest earnings beat: Tango reported Q4 EPS of ($0.29), beating consensus of ($0.31) by $0.02, while shares traded at $16.58 on heavy volume and the company carries a ~$2.23 billion market cap.
• Positive catalysts driving momentum: Multiple analysts raised price targets (e.g., HC Wainwright to $27, Guggenheim to $20), and a new codevelopment deal with Erasca plus a roughly $9.5M institutional share purchase have supported recent buying interest.
• Profitability risks persist: Despite the beat and analyst optimism, Tango remains unprofitable with a negative net margin (~151%) and negative return on equity (~60.8%), highlighting longer‑term financial risk.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.02, FiscalAI reports. Tango Therapeutics had a negative return on equity of 60.80% and a negative net margin of 151.15%.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock traded down $0.25 on Friday, reaching $16.58. 3,756,230 shares of the company were exchanged, compared to its average volume of 3,354,465. The stock's 50 day moving average price is $11.70 and its 200-day moving average price is $9.37. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $17.63. The company has a market cap of $2.23 billion, a P/E ratio of -17.83 and a beta of 1.76.

Key Stories Impacting Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target sharply to $27 and reiterated a buy rating, implying ~61% upside from the referenced price. This is the most bullish analyst move and likely helped momentum. HC Wainwright Boost Ticker Report
• Positive Sentiment: Guggenheim raised its target to $20 with a buy rating (≈19.5% upside), adding institutional credibility to the rally. Guggenheim Note
• Positive Sentiment: Wedbush boosted its target to $19 and moved to outperform (~13.5% upside), contributing to analyst-driven buying interest. Wedbush Note
• Positive Sentiment: Tango announced a codevelopment deal with Erasca that analysts and press flagged as a material commercial/clinical partnership — a key fundamental catalyst behind recent gains. Erasca Deal
• Positive Sentiment: A large investment firm purchased roughly $9.5M of TNGX shares (SEC filing), increasing institutional ownership and signaling conviction from a fund buyer. Institutional Purchase
• Neutral Sentiment: Q4 results: EPS of ($0.29) beat consensus ($0.31) by $0.02 — a modest beat, but still a cash‑burning biotech profile. See the company release for details. Q4 Press Release
• Neutral Sentiment: Market commentary and “earnings to watch” pieces circulated ahead of/after the print; these amplified volatility but didn’t change fundamentals alone. Earnings to Watch
• Negative Sentiment: Despite the beat, Tango remains unprofitable with a negative net margin (~151%) and negative return on equity — underlying profitability risks remain for longer‑term investors. Profitability Metrics

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Piper Sandler boosted their price objective on Tango Therapeutics from $11.00 to $14.00 and gave the company an "overweight" rating in a report on Friday, January 16th. Guggenheim boosted their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Friday. Stifel Nicolaus began coverage on shares of Tango Therapeutics in a research report on Wednesday, December 3rd. They set a "buy" rating and a $15.00 price target on the stock. Wedbush lifted their price objective on shares of Tango Therapeutics from $15.00 to $19.00 and gave the company an "outperform" rating in a report on Friday. Finally, Mizuho initiated coverage on shares of Tango Therapeutics in a research note on Monday, February 23rd. They set an "outperform" rating and a $19.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Tango Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $18.25.

Insider Buying and Selling

In other Tango Therapeutics news, CFO Daniella Beckman sold 10,317 shares of the firm's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $126,486.42. Following the sale, the chief financial officer directly owned 184,297 shares in the company, valued at $2,259,481.22. This trade represents a 5.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Adam Crystal sold 54,345 shares of Tango Therapeutics stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $12.77, for a total value of $693,985.65. Following the sale, the insider directly owned 132,873 shares of the company's stock, valued at $1,696,788.21. This trade represents a 29.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 113,633 shares of company stock worth $1,420,857 over the last 90 days. 7.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Tango Therapeutics

Several large investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd increased its position in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock worth $35,000 after purchasing an additional 15,037 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Tango Therapeutics during the fourth quarter worth approximately $35,000. Legal & General Group Plc lifted its stake in Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company's stock valued at $36,000 after buying an additional 1,640 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Tango Therapeutics by 44.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company's stock valued at $49,000 after acquiring an additional 2,907 shares during the period. Finally, Northeast Financial Consultants Inc acquired a new stake in shares of Tango Therapeutics in the second quarter valued at approximately $51,000. Institutional investors and hedge funds own 78.99% of the company's stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.